Biocon Biologics (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK (ustekinumab-kfce) is now available to ...

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Drug development powered by artificial intelligence is countering incentives from the Inflation Reduction Act and making ...

Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of ...

From treating sickle cell anaemia to aiding spinal injury recovery, this breakthrough treatment marks a new era of ...

One of the hostages released on Saturday, February 22, by the terrorist organization Hamas also holds Romanian citizenship.

Examining the carnivore diet: potential benefits for weight loss and inflammation versus risks of nutrient deficiencies and ...

WHO and Encephalitis International urged policymakers, public health professionals, healthcare providers, and researchers to ...

Celltrion's Avtozma, a biosimilar to Actemra, was approved by the European Commission for sale in member states.

South Korean pharmaceutical firm Celltrion announced Monday that Avtozma, a biosimilar of Actemra, has received approval from the European Commission. The approval covers major indications of the ...

Cindy Cox has been battling a debilitating autoimmune disease that has taken a toll on her health, her strength, and her ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...